420 with CNW — Pittcon Research Could Help Regulate Levels of Synthetic and Natural Cannabinoids
Psychedelics and cannabis are probably two of the most common psychoactive drugs, or substances that change physiological and psychological functions. These drugs can affect daily life in both negative and positive ways when used.
For instance, when administered correctly, cannabis may be used as a therapeutic option for a range of neurological conditions such as Alzheimer’s, Parkinson’s and brain cancer. Contrarily, recreational cannabis has been linked to issues with mood, cognition and other symptoms.
Cannabinoids, which are naturally occurring substances in the marijuana plant, are what cause the drug’s psychological and physical side effects. The most popular cannabinoids are tetrahydrocannabinol (THC), cannabidiol (CBD) and cannabigerol (CBG). While THC gives cannabis its “high,” CBD and CBG affect pain perception, appetite and memory and are primarily used to treat diseases such as multiple sclerosis and reduce inflammation and anxiety.
The increased legalization of cannabis has led to the emergence of many products that are now available for both recreational and medical use. But to keep up with the rapidly evolving cannabinoid market, there is now a need to diversify policies in public health.
Developing novel methods for analyzing psychoactive substances using techniques such as liquid chromatography, gas chromatography and mass spectrometry can assist in addressing some of the cannabis therapeutic and regulatory issues.
On the flip side, synthesized cannabinoids are artificial chemicals that mimic the effects of marijuana but are more hazardous as a food additive than natural cannabinoids because they are less well-known, less predictable and have unpredictable effects. Sometimes, producers of marijuana-based products add synthetic cannabinoids to their products because they are easier, quicker and cheaper to produce. Consumers are at risk from this practice, however, as it increases the likelihood of product contamination and lowers quality. Synthetic cannabinoids can also have negative side effects and are difficult to regulate.
The development of innovative drugs will play a significant role in the rapid, efficient and accurate identification and quantification of both natural and synthetic cannabinoids, which will be a major step toward developing regulatory policy and implementing health interventions. As a result, more research on cannabinoids’ effects and biochemistry is required.
Pittcon is at the leading edge of this research, pushing the boundaries of study into psychoactive substances. Researchers are expected to present a number of studies that have examined marijuana and other psychoactive substances at Pittcon this year. The presentations will be crucial to advancing innovation in the cannabis and psychedelics industries, assisting in the better formulation of strategies to curtail the inappropriate use of these substances and develop potential medical treatments.
Industry experts and scientists will highlight the technologies and methodologies used to identify and measure levels of cannabinoids as well as evaluate the quality of cannabinoid products on legal and illegal markets.
As more resources are directed towards understanding both natural and synthetic cannabinoids, innovative products, such as indoor “microgardens” from manufacturers like Advanced Container Technologies Inc. (OTC: ACTX) are also becoming available on the market across the country.
NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Psychedelics and cannabis are probably two of the most common psychoactive drugs, or substances that change physiological and psychological functions. These drugs can affect daily life in both negative and positive ways when used.
For instance, when administered correctly, cannabis may be used as a therapeutic option for a range of neurological conditions such as Alzheimer’s, Parkinson’s and brain cancer. Contrarily, recreational cannabis has been linked to issues with mood, cognition and other symptoms.
Cannabinoids, which are naturally occurring substances in the marijuana plant, are what cause the drug’s psychological and physical side effects. The most popular cannabinoids are tetrahydrocannabinol (THC), cannabidiol (CBD) and cannabigerol (CBG). While THC gives cannabis its “high,” CBD and CBG affect pain perception, appetite and memory and are primarily used to treat diseases such as multiple sclerosis and reduce inflammation and anxiety.
The increased legalization of cannabis has led to the emergence of many products that are now available for both recreational and medical use. But to keep up with the rapidly evolving cannabinoid market, there is now a need to diversify policies in public health.
Developing novel methods for analyzing psychoactive substances using techniques such as liquid chromatography, gas chromatography and mass spectrometry can assist in addressing some of the cannabis therapeutic and regulatory issues.
On the flip side, synthesized cannabinoids are artificial chemicals that mimic the effects of marijuana but are more hazardous as a food additive than natural cannabinoids because they are less well-known, less predictable and have unpredictable effects. Sometimes, producers of marijuana-based products add synthetic cannabinoids to their products because they are easier, quicker and cheaper to produce. Consumers are at risk from this practice, however, as it increases the likelihood of product contamination and lowers quality. Synthetic cannabinoids can also have negative side effects and are difficult to regulate.
The development of innovative drugs will play a significant role in the rapid, efficient and accurate identification and quantification of both natural and synthetic cannabinoids, which will be a major step toward developing regulatory policy and implementing health interventions. As a result, more research on cannabinoids’ effects and biochemistry is required.
Pittcon is at the leading edge of this research, pushing the boundaries of study into psychoactive substances. Researchers are expected to present a number of studies that have examined marijuana and other psychoactive substances at Pittcon this year. The presentations will be crucial to advancing innovation in the cannabis and psychedelics industries, assisting in the better formulation of strategies to curtail the inappropriate use of these substances and develop potential medical treatments.
Industry experts and scientists will highlight the technologies and methodologies used to identify and measure levels of cannabinoids as well as evaluate the quality of cannabinoid products on legal and illegal markets.
As more resources are directed towards understanding both natural and synthetic cannabinoids, innovative products, such as indoor “microgardens” from manufacturers like Advanced Container Technologies Inc. (OTC: ACTX) are also becoming available on the market across the country.
NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
